Chronic hypoxia is an inciting factor for the development of pulmonary arterial hypertension. The mechanisms involved in the development of hypoxic pulmonary hypertension (HPH) include hypoxia-inducible factor 1 (HIF-1)-dependent transactivation of genes controlling pulmonary arterial smooth muscle cell (PASMC) intracellular calcium concentration ([Ca 2+ ] i ) and pH. Recently, digoxin was shown to inhibit HIF-1 transcriptional activity.
Contributed by Gregg L. Semenza, December 12, 2011 (sent for review August 30, 2011) Chronic hypoxia is an inciting factor for the development of pulmonary arterial hypertension. The mechanisms involved in the development of hypoxic pulmonary hypertension (HPH) include hypoxia-inducible factor 1 (HIF-1)-dependent transactivation of genes controlling pulmonary arterial smooth muscle cell (PASMC) intracellular calcium concentration ([Ca 2+ ] i ) and pH. Recently, digoxin was shown to inhibit HIF-1 transcriptional activity.
In this study, we tested the hypothesis that digoxin could prevent and reverse the development of HPH. Mice were injected daily with saline or digoxin and exposed to room air or ambient hypoxia for 3 wk. Treatment with digoxin attenuated the development of right ventricle (RV) hypertrophy and prevented the pulmonary vascular remodeling and increases in PASMC [Ca 2+ ] i , pH, and RV pressure that occur in mice exposed to chronic hypoxia. When started after pulmonary hypertension was established, digoxin attenuated the hypoxia-induced increases in RV pressure and PASMC pH and [Ca 2+ ] i . These preclinical data support a role for HIF-1 inhibitors in the treatment of HPH.
acriflavine | cardiac glycosides | pulmonary circulation P rolonged exposure to hypoxia occurs in physiological and pathological contexts, such as during a high-altitude sojourn or as a result of chronic obstructive pulmonary disease, respectively. Chronic hypoxia (CH) triggers maladaptive responses in the lung vasculature, leading to the development of hypoxic pulmonary hypertension (HPH) (1) . Typically, HPH results from arteriolar constriction followed by vascular wall remodeling, which includes both thickening of the wall due to smooth muscle cell (SMC) and fibroblast proliferation, as well as extension of SMCs into previously nonmuscular precapillary arterioles. Over time, HPH causes right ventricle hypertrophy (RVH), which can lead to right ventricular (RV) failure and death.
Although incompletely understood, some of the alterations in pulmonary arterial SMCs (PASMCs) that underlie the development of HPH have been delineated (2, 3) . For example, in HPH, alterations in Ca 2+ and pH homeostasis contribute to growth and contraction of PASMCs. Our previous work demonstrated that HPH is characterized by increased PASMC intracellular pH (pH i ) due to increased activity and expression of Na + /H + exchanger isoform 1 (NHE1) (4, 5) , and elevated intracellular Ca 2+ concentration ([Ca   2+ ] i ) (6) due to increased expression of canonical transient receptor potential (TRPC) proteins and enhanced Ca 2+ entry through nonselective cation channels (7) . Critical aspects of the pathogenesis of HPH, including both the increase in basal [Ca 2+ ] i and alkalinization of PASMCs, are mediated by hypoxia-inducible factor 1 (HIF-1) (5, (7) (8) (9) .
HIF-1 is a heterodimeric transcription factor composed of HIF-1α and HIF-1β subunits that regulates the expression of hundreds of genes in response to hypoxia, including many genes associated with HPH (10) . HIF-1β is ubiquitously expressed, whereas HIF-1α expression is O 2 -regulated (11, 12) . Under normoxic conditions, HIF-1α is hydroxylated on two proline residues by prolyl hydroxylase domain proteins, which use O 2 as a substrate, marking the protein for ubiquitination and proteasomal degradation (13, 14) . Under hypoxic conditions, HIF-1α accumulates and dimerizes with HIF-1β, allowing for the transcription of target genes. The ability to target HIF-1α would allow control of the expression of genes associated with the pathology of many diseases, including HPH.
Screening of the Johns Hopkins Drug Library, a collection of 3,120 clinically used compounds, revealed that all 11 cardiac glycosides tested inhibit HIF-1α, indicating a class effect (15) . One member of this class, digoxin, inhibited HIF-1α protein translation and blocked HIF-1 activity in vivo (15, 16) . Digoxin has been used for decades to treat heart failure on the basis of its inotropic potential, an effect that is most likely due to inhibition of the Na + /K + ATPase. Given the central role of HIF-1 in the development of HPH, we hypothesized that digoxin would attenuate the pulmonary vascular effects of CH in a murine model of HPH.
Results

Effect of Digoxin on Body Weight (BW).
In the prevention protocol, mice were exposed to room air (21% O 2 ; normoxia) or to 10% O 2 (CH) for 3 wk to induce HPH while receiving daily injections of saline or digoxin at a dose of 1.0 mg/kg. Plasma digoxin levels measured 24 h after the final injection (Fig. S1A ) were found to be at or below the therapeutic range for humans (0.5-2 ng/mL). BW increased in normoxic animals over 3 wk (Fig. S1B ). All hypoxic mice experienced a sharp initial decrease in BW, but by day 5 mice receiving digoxin began to exhibit weight gain, eventually reaching 93.2% ± 2.4% of initial BW. Mice receiving saline began to gain weight by day 9-10, reaching 86.7% ± 1.3% of initial BW after 3 wk.
Effect of Digoxin on Hematocrit (Hct). Prolonged exposure to hypoxia results in polycythemia via HIF-dependent induction of erythropoietin expression. In normoxic animals, Hct was similar in both saline-and digoxin-treated mice, with all values below 40% (Fig. S1C) . In contrast, all animals exposed to CH experienced increased Hct levels, although values were significantly lower in hypoxic mice receiving digoxin.
Effect of Digoxin on RV Pressure and Heart Weight. RV pressure readings (Fig. 1A) and heart weights were used to evaluate the effects of digoxin on the development of HPH. In normoxic mice, average RV systolic pressure (RVSP) was ≈20 mm Hg (Fig. 1B) . RVSP in saline-treated chronically hypoxic mice was elevated. In hypoxic mice receiving digoxin, RVSP was significantly reduced compared with mice that received saline and was not statistically different from normoxic levels (Fig. 1C) . Digoxin had no significant effect on heart rate (Table S1 ). In normoxic mice, digoxin had no effect on RV weight when normalized to BW (Table S1 ) or to combined weight of the left ventricle and septum (LV+S) (Fig. 1D) . After exposure to CH, RV weight increased in mice receiving saline, whereas a much smaller increase in RV weight was observed in chronically hypoxic mice treated with digoxin (Table S1 ). Similar results were observed when RV weight was normalized to LV+S weight (Fig. 1D) . ] i , whereas digoxin had no effect on pH i (Table S2 ). Acute exposure of PASMCs from hypoxic mice to digoxin had no effect on either [Ca 2+ ] i or pH i .
Effect of Digoxin on Pulmonary Vascular Remodeling. The increase in pulmonary arterial pressure in response to CH occurs, in part, because of remodeling of the pulmonary vasculature. Extension of smooth muscle into previously nonmuscular vessels can be observed as an increase in small diameter vessels (<100 μm outer diameter) that are positive for smooth muscle-specific α-actin (SMA). In lungs from normoxic mice receiving saline or digoxin, the percentage of SMA-positive vessels was ≈30-40% (Fig. 2C ).
In saline-treated hypoxic mice, the number of small vessels exhibiting a complete muscle layer increased to nearly 90%. Significantly fewer SMA-positive vessels were observed in the lungs of digoxin-treated hypoxic mice. (mean ± SEM) shows effect of digoxin on RVSP. Mice were injected with saline or 1 mg/kg digoxin per day (n = 6 for Nor-saline, n = 7 for Hyp-saline, n = 8 for Nor-digoxin, and n = 7 for Hyp-digoxin). (D) Effect of digoxin treatment on RVH. Bar graphs (mean ± SEM) show RV/LV+S weight ratio in mice exposed to normoxia or hypoxia in the absence or presence of digoxin (n = 8 for Nor-saline and Hyp-saline; n = 9 for Nor-digoxin and Hyp-digoxin). *Significant difference compared to normoxia value of the same treatment; † significant difference compared to Hyp-saline. Effect of Digoxin on HIF-1 Target Genes. We previously reported that the increase in PASMC [Ca 2+ ] i and pH i in response to hypoxia is due to HIF-1-dependent transcriptional activation of the Trpc1 and Nhe1 genes, respectively (5, 7). We found that levels of mRNA encoding TRPC1 and NHE1, as well as the classic HIF-1 target glucose transporter 1 (GLUT1), were increased in lung tissue from chronically hypoxic mice (Fig. 3A) . The hypoxia-induced increase in mRNA levels for all HIF-1 target genes was not observed in lungs from chronically hypoxic mice treated with digoxin. To further confirm that digoxin could prevent HIF-1-dependent alterations in PASMCs, cells from normoxic animals were cultured under hypoxic conditions (4% O 2 ; 60 h) in the presence of digoxin (100 nM) or vehicle. Digoxin treatment completely prevented the hypoxia-induced increase in GLUT1, TRPC1, and NHE1 mRNA levels (Fig. 3B) .
Effect of Digoxin on Established HPH. To evaluate the ability of digoxin to reverse established HPH, mice were exposed to 10% O 2 for 3 wk. After development of HPH, mice received daily injections of saline or digoxin (0.2 or 1.0 mg/kg) and were exposed to hypoxia for an additional 2 wk. At the end of the hypoxic exposure (5 wk total), there were no significant differences in Hct, BW, or LV weight among the three groups (Table  S1 ). Both RV weight and RV weight/BW ratio were significantly reduced in mice treated with digoxin (Table S1 ). Digoxin treatment also resulted in significantly lower RVSP (Fig. 4A ) compared with mice receiving saline. The RV/LV+S weight ratio was lower in digoxin-treated mice (0.29 ± 0.01 for 0.2 mg/kg and 0.308 ± 0.01 for 1 mg/kg; n = 7 each) compared with those receiving saline (0.327 ± 0.01; n = 8), but the difference did not reach statistical significance (P = 0.096). In a subset of mice, lung histology was examined for evidence of vascular remodeling. Similar to mice exposed to saline in the prevention protocol, mice in the reversal protocol exhibited an increase in the percentage of SMA-positive small-diameter vessels. Administration of digoxin had no significant effect on vascular remodeling, with all hypoxic groups exhibiting >80% SMA-positive vessels. As expected, both pH i and [Ca 2+ ] i were elevated in PASMCs isolated from mice receiving saline (Fig. 4 B and C) . Digoxin treatment markedly reduced both pH i and [Ca 2+ ] i in PASMCs from mice exposed to 5 wk of hypoxia.
Effect of Acriflavine on HPH. To further evaluate the effect of pharmacologic inhibition of HIF activity on HPH and to confirm that the effects of digoxin were not due to HIF-independent actions, prevention experiments were also performed with a different HIF inhibitor, acriflavine, which does not affect HIF-1α synthesis but inhibits the dimerization of HIF-1α with HIF-1β (17) . Furthermore, the experiments were performed with rats exposed to CH, which represents a more robust model of HPH. Daily administration of acriflavine had no effect on normoxic rats but significantly reduced RVSP (Fig. 5A) , RVH (Fig. 5B) , the percentage of SMA-positive small-diameter vessels (Fig. 5C) , and PASMC resting [Ca 2+ ] i (Fig. 5D ) in rats subjected to CH.
Discussion
In the present study, we show that administration of digoxin, which inhibits HIF-1α synthesis and HIF-1 transcriptional activity (15, 16), prevents the development and slows the progression of HPH in a murine model. Although the doses of digoxin administered in our study are higher than those administered to humans, comparison of dosages between species is complicated by a number of factors. For example, on the basis of BW vs. surface area measurements, it has been suggested that a given dosage in humans requires a 12-fold higher dose in mice (18) . Drug metabolism can also vary considerably owing to differential mechanisms of uptake, clearance, and/or degradation (19) . With these caveats in mind, plasma digoxin levels measured in this study were at or below the therapeutic range for humans. Weight loss associated with exposure to CH was reduced in mice treated with digoxin, suggesting that digoxin was well tolerated. This finding was surprising because HIF-1α heterozygous-null mice, which were protected from HPH, lost more weight during CH than wild-type mice (9) . The reason for the difference in weight gain between these studies is unclear, but it could be due to several factors, including variable drug penetration among tissues or the use of different strains of mice.
In the prevention protocol, digoxin normalized RVSP. Intriguingly, digoxin reduced but did not normalize RVH. It is doubtful that the discrepancy between RVSP and RVH was due to a component of RVSP that rapidly reversed upon reoxygenation, because we previously demonstrated that RV pressures were minimally higher in chronically hypoxic mice ventilated with 10% O 2 compared with reoxygenated animals (9). Although cardiac glycosides can cause cardiac hypertrophy (20) (21) (22) , it is unlikely that digoxin had a direct hypertrophic effect, given that heart weights were unchanged in the normoxic mice. A plausible explanation is that there is a direct effect of hypoxia on the RV that is independent of HIF-1 or the pulmonary vascular effects of hypoxia (i.e., PH), a hypothesis that is supported by a recent study in which RVH was decoupled from PH in hemeoxygenase-1-deficient mice that received supplemental carbon monoxide or biliverdin (23) . Further testing will be required to determine the mechanism by which RVH occurs during CH and to determine whether treatment with digoxin can alter longterm survival.
The effect of digoxin on Hct was modest but still significantly reduced compared with animals receiving saline. The small effect on Hct could be due to lower drug penetration in the tissues where erythropoietin is produced (i.e., kidney and liver). Alternatively, it has been proposed that in vivo, erythropoietin expression is driven predominately by HIF-2α (24, 25) , which exhibits reduced sensitivity to digoxin compared with HIF-1α (15) . Consistent with this possibility, the reduction in CH-induced polycythemia in mice with partial deficiency for HIF-1α was modest, albeit statistically significant (9) . In either case, the fact that therapeutic concentrations of digoxin normalized RVSP and reduced RVH while maintaining slightly elevated Hct might prove beneficial in improving O 2 transport while reducing HPH.
Digoxin had profound effects on PASMC [Ca 2+ ] i and pH i during CH. We previously demonstrated that HPH was associated with increased [Ca 2+ ] i , which is HIF-1-dependent, mediated by increased TRPC expression, and likely contributes to increased PASMC contraction and proliferation (6, 7) . In the presence of digoxin, the reduction in [Ca 2+ ] i in PASMCs from chronically hypoxic mice was correlated with an absence of hypoxia-induced induction of TRPC1 mRNA expression. Similarly, digoxin prevented the hypoxia-induced elevation in pH i , which is due to HIF-1-dependent induction of NHE1 mRNA and protein.
Initiating digoxin treatment after HPH and changes in ion homeostasis were established still resulted in a near normalization of pH i and [Ca 2+ ] i , indicating significant plasticity in these responses. Despite the dramatic reduction in both pH i and [Ca 2+ ] i with digoxin treatment and the fact that RVSP was reduced, vascular remodeling was unaltered, suggesting that once established, 2 wk may be insufficient time to reverse changes in muscularity of the small vessels or that HIF-1-dependent vascular remodeling may be an early response to hypoxic exposure and once initiated is maintained via HIF-independent mechanisms. Nonetheless, the reductions in RVSP, PASMC [Ca 2+ ] i , and pH i observed in digoxin-treated mice, coupled with the lack of effect of digoxin on remodeling, suggests that at these later time points a reduction in vascular tone may have played a more prominent role in decreasing pulmonary arterial pressure.
Digoxin inhibits HIF-1 transcriptional activity by preventing HIF-1α protein translation (15, 16) , consistent with the lack of hypoxic induction of HIF-1 target genes in lungs from chronically hypoxic animals and in PASMCs exposed to hypoxia ex vivo. Even so, it is also possible that the observed results in digoxintreated animals may be due, in part, to modulation of HIF-1-independent pathways, such as inhibition of Na + /K + ATPase, which could result in elevated intracellular [ (29) (30) (31) and cardiac output (32) and had no effect on (32, 33) or accentuated (34) hypoxic pulmonary vasoconstriction. These findings would argue against a role for blockade of Na + / K + ATPase as the mechanism by which digoxin inhibited HPH. Moreover, the effects of digoxin on HPH were replicated by treatment with acriflavine, which inhibits HIF activity by a distinct molecular mechanism (17) . Thus, although we cannot ] i (mean ± SEM) in PASMCs from normoxic and hypoxic rats treated with saline (n = 94 cells from five rats for normoxia and 92 cells from five rats for hypoxia) or acriflavine (n = 100 cells from five rats for normoxia and 110 cells from five rats for hypoxia).
completely rule out HIF-1-independent effects of digoxin, our data suggest that the ability of digoxin to lower [Ca 2+ ] i and pH i and prevent vascular remodeling was most likely due to inhibition of HIF-1.
In summary, we found that treatment with digoxin prevented the changes in pulmonary vascular [Ca 2+ ] i , pH i , remodeling, and pressure that occur in mice exposed to CH, offering further evidence that HIF-1 plays a critical role in the development of HPH. Furthermore, administration of digoxin after HPH was established reduced RVSP and corrected Ca 2+ and pH homeostasis, demonstrating the ability of this agent to slow the progression of HPH. Although the present study was restricted to HPH, other forms of PH are also associated with elevated levels of HIF-1α in the lung (35, 36) and similar defects in PASMC function (2, 3) , suggesting the possibility that digoxin might reduce pulmonary vascular pressure and remodeling in non-hypoxia-associated PH. Digoxin has been proposed for use in the treatment of PH with associated RV failure as a means to increase cardiac contractility and output (37, 38) . However, given the small therapeutic window in humans, possible issues of toxicity in the chronic obstructive pulmonary disease patient population (39, 40) , and a lack of data supporting a positive effect of digoxin on survival, the use of this drug in patients with PH and RV failure remains controversial, and to date no clinical trials have been performed to evaluate its ability to lower pulmonary arterial pressure. In a disease for which treatment options are limited, this study provides "proof of concept" that HIF-1 inhibitors could be beneficial and suggests that further investigation is warranted.
Materials and Methods
In Vivo Exposure to CH. All protocols were approved by The Johns Hopkins University Animal Care and Use Committee. Adult male C57BL/6J mice (8-10 wk; Jackson Laboratory) were placed in a chamber maintained at 10% O 2 for 3 wk, as previously described (5, 7). The chamber was constantly flushed with room air to maintain low (<0.5%) CO 2 concentrations. A servo-control system (PRO-OX; Hudson RCI) monitored O 2 levels and injected 100% N 2 as needed to maintain 10% ± 0.5% O 2 . Cages were cleaned and food and water replenished twice per week. Normoxic animals were kept in room air on a wire rack adjacent to the chamber. Animals were allowed free access to food and water. In the prevention protocol, beginning the day before the hypoxic exposure, mice were weighed and injected daily with digoxin (1.0 mg/kg i.p.), which was diluted in four times the volume of sterile saline, or injected with an equal volume of sterile saline. In the reversal protocol, mice were exposed to CH for 3 wk to establish HPH before being weighed and injected daily with saline or digoxin (0.2 or 1 mg/kg) during an additional 2 wk of hypoxic exposure. Injectable digoxin (Sandoz; 0.25 mg/mL) was obtained from The Johns Hopkins Hospital Research Pharmacy and was diluted in sterile saline before injection. For acriflavine experiments, adult male Wistar rats (Harlan; starting weight 250 g) were weighed daily, and saline or acriflavine (2 mg/kg in a total volume of 600 mL) was administered i.p. (17) starting the day before hypoxic exposure. Acriflavine (Sigma Aldrich) was obtained in crystalline form and dissolved in sterile PBS. Unless otherwise specified, all other reagents were obtained from Sigma Aldrich. All data were obtained by investigators blinded to treatment status.
RV Pressure. Closed-chest RV pressure was measured in anesthetized mice through an abdominal incision, as previously described (9) . Mice were anesthetized with sodium pentobarbital (60 mg/kg), the diaphragm visualized through the abdomen, and RV pressure measured via a 23-gauge needle filled with heparinized saline and connected to a pressure transducer (model P10EZ; Spectramed). Correct localization of the puncture was verified by postmortem inspection. Pressure was recorded using Power Lab Software (ADI Instruments). Only mice in which stable tracings were obtained and RV puncture was verified were included in the analysis.
Hct and Digoxin Measurements. Blood was collected from the LV and placed in EGTA-treated tubes. The blood was mixed and a small amount drawn into a capillary tube, the plasma separated via low-speed centrifugation, and Hct measured using a microhematocrit capillary tube reader chart. The remaining blood was centrifuged and the plasma collected and frozen at −80°C until use. Plasma digoxin levels were determined using a commercially available kit (Monobind) according to manufacturer's instructions.
RVH Determination. Under a dissecting microscope, the atria and extraneous vascular material were removed from the heart. The RV wall was carefully separated from the LV+S, and both portions were quickly blotted dry and weighed.
Isolation of PASMCs. Intralobar pulmonary arteries (100-400 μm outer diameter) were dissected and cleaned of connective tissue in ice-cold Hepesbuffered saline solution (HBSS) containing (in mM): 130 NaCl, 5 KCl, 1.2 MgCl 2 , 10 Hepes, and 10 glucose with pH adjusted to 7.2 with 5 M NaOH, as previously described (2) . The arteries were opened and the lumen gently rubbed to remove the endothelium. Cleaned arteries were allowed to recover for 30 min in cold (4°C) HBSS followed by 20 min in reduced-Ca 2+ HBSS (20 μM CaCl 2 ) at room temperature. After recovery, the tissue was incubated for 10 min (mice) or 20 min (rats) at 37°C in reduced-Ca 2+ HBSS containing collagenase (type I; 1,750 U/mL), papain (9.5 U/mL), BSA (2 mg/mL), and DTT (1 mM Lung Histology. A suture was used to occlude the right lung, which was removed for isolation of PASMCs. A cannula was inserted into the trachea, and the left lung was inflated with 0.5 mL of 10% formalin, transferred to 70% ethanol, embedded in paraffin, and sectioned into 5-μm slices. Sections were subjected to antigen retrieval, blocked, stained with SMA antibody (Sigma Aldrich) overnight at 4°C, and incubated with CY3-conjugated secondary antibody (Molecular Probes) for 1 h at room temperature. Each lung section was evaluated by a blinded investigator for the presence of SMA-positive small-diameter vessels (outer diameter ≤100 μm) using confocal microscopy (LSM-510; Zeiss). Vessels were randomly identified via light microscopy and then scanned at 560 nm to evaluate the presence of SMA. For each lung, 20 randomly selected vessels were scored, and the percentage of SMA-positive vessels was calculated.
Real-Time RT-PCR. The methods for isolation of total RNA and real-time RT-PCR have been previously described (41) . Primer sequences specific for mouse TRPC1, NHE1, GLUT1 and cyclophilin mRNA were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) and are listed in Table S3 . Specificity of quantitative PCR products was confirmed by the observation of a single peak in the melting curve performed after cDNA amplification and a single band of expected size on an agarose gel, which was then excised and sequenced at The Johns Hopkins Sequencing facility. The relative expression of each mRNA was determined using the Pfaffl method (42) fold change values were subjected to arctangent conversion, before statistical analysis. Unless otherwise noted, data were compared group-wise as a single analysis using a two-way ANOVA with a Holms-Sidak post hoc test to determine differences between groups. A P value <0.05 was accepted as statistically significant.
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